Efficiency in R&D is calculated more often than not through the return on investments made on therapeutic candidates, when they reach their commercialization stage and are able to earn revenue for the company who has developed it.
- Such efficiency, however, has been declining in the Pharma R&D sector, which propels decision makers and CXOs to assess the relevancy of their portfolios in early stage of development itself.
- Assessing portfolio risk through assessment of candidate’s projected success and understanding ways of reducing cost of R&D are some ways which can help benchmark candidates of interest against the market parameters of success.
- Moreover, understanding competition at an early stage creates a foundation of assessing future market shares and decide candidate’s potential niche area in the market.
Our Perspective
The most basic way to understand the candidate’s journey through pre-clinical and clinical development is by assessing the same parameters of other candidates already in the space. To help pharmaceutical companies assess the current scenario of a particular indication, or a particular Mechanism of Action, or a particular Active Pharmaceutical Ingredient, or a particular Drug candidate, etc. DelveInsight’s insight-packed reports provide clarity on uncertainties and challenge blind spots to provide timely intelligence to the company.
Our R&D Analysis Service Provides:
- Comparative Analysis
- A Drug candidate’s overall developmental landscape
- In-depth insights on Regulatory Milestones
- Therapeutic Assessment
- Details of asset-based collaborations and partnerships
- Developmental Milestones of therapies of a particular indication, MoA, API etc.
Related Insights
R&D Analysis
A mid-Pharma client based in India involved DelveInsight to assist in gathering and analyzing congress abstracts and literature review from various congresses for Parkinson’s disease.
Read More
Competitive Landscape Assessment
A large medical device client, based in the United States, with capabilities in drug delivery medical devices, involved DelveInsight to assess the potential risks and benefits of a...
Read More
Portfolio Management
A small-Pharma client based in Israel involved DelveInsight to manage their portfolio of candidates indicated for various infectious diseases.
Read More
Asset Prioritization
A mid-sized pharma client was working to develop their asset portfolio, and was interested to assess best possible asset for atrial fibrillation
Read More